Navigation Links
Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/26/2008

tion. Such factors include, among others, the possibility that immunology responses may not be a predictor of clinical benefit; that immunological findings in our first two cohorts may not be consistent with findings from our third and fourth cohorts and future clinical studies; that safety and tolerability findings in our first three cohorts may not be consistent with findings from our fourth cohort and future clinical studies; that results from future clinical trials will not be consistent with our expectations; that we will not be able to recruit patients for our planned trials in a timely manner; our need for capital; risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for obtaining clinical supply materials; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that immunology responses are a predictor of clinical benefit; that immunological findings in our first two cohorts will be consistent with findings from our third and fourth cohorts and future clinical studies; that safety and tolerability findings in our first two cohorts will be consistent with findings from our third and fourth cohorts and future clinical studies; that results from future c
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
3. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
6. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
7. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
8. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
9. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
11. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... be an alternative therapy for Parkinson,s , NEW YORK, ... University Medical Center have reached a milestone in the development ... the limitations of current therapy. , The team, which received ... Foundation,s 2007 LEAPS (Linked Efforts to Accelerate Parkinson,s Solutions) ...
... Sept. 30 InteKrin Therapeutics Inc. announced today positive ... safety studies. Data will be presented at the ... Meeting in Vienna, Austria at 12:45 PM ... Officer, Linda Higgins, PhD, in a presentation "Chronic Cardiovascular ...
Cached Medicine Technology:Michael J. Fox Foundation-Funded Team Pursuing Glutamate-Based Treatment for Parkinson's Disease Hits Major Milestone 2InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting 2
(Date:4/24/2014)... a better understanding of drug interactions, which are a ... When two or more medications are taken at the ... of the other. Similarly, one drug may magnify ... a major cause of illness and hospitalization. However, ... of drug studies in humans. Limits come in ...
(Date:4/24/2014)... outcomes for parents who have a child born with ... recent study led by a researcher at the University ... life-changing and stress levels high, the vast majority of ... outcomes as well, a phenomenon known as posttraumatic growth. ... the American Journal of Orthopsychiatry . , "What ...
(Date:4/24/2014)... WINSTON-SALEM, N.C. April 24, 2014 ,Take me ... of apple slices and kale chips. The more likely ... of Crackerjacks. , Unfortunately for children who play ... may be contributing to weight problems, according to researchers ... in the current online edition of Childhood Obesity ...
(Date:4/24/2014)... 28, the Center for BrainHealth will bring together ... pressing brain-related challenges at its inaugural Brain Health ... Regeneration." Featured speakers will include Dr. Sandra Bond ... for BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. ... Assistant Secretary for Policy and Early Learning, U.S. ...
(Date:4/24/2014)... and irrelevant, could offer an alternative to heart transplants ... Furtado, and her team from the Australian Regenerative Medicine ... fibroblast is a close relative to a cardiomyocyte, the ... research published today in Circulation Research , Dr ... due to their genetic program, and will aid in ...
Breaking Medicine News(10 mins):Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Take the bat, leave the candy 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Boring cells could hold the key to heart disease 2
... But what about homosexual partnerships? Are they made for each ... a while, and now it seems like the battle lines ... ,The U.S. president, during a recent radio address, has ... Bush said 'This national question requires a national solution, and ...
... the London School of Medicine and Dentistry has called ... the UK//. Len Doyal a professor of medical ethics ... ,The professor believes that doctors should be able ... in an article that was published today in the ...
... an United nation official, a campaign to warn Indonesians ... year after the virus infected //the first of 49 people ... country in the world. ,According to John Budd, ... Jakarta, thousands of government workers and several members of ...
... and Jehangir Sabavala displayed their work on ‘Visual Trajectories’ ... held at Durban for a period of 3 weeks ... co-operation between Indian and South African Governments, an agreement ... African National Gallery (Iziko Sang) and National Gallery of ...
... The discovery of a 170cm tall adult human skeleton ... conspicuous', says Mishra. // ,'A lot of ... related to the culture, customs, lineage or gene-pool, birth, ... Mishra says., ,The Abhaipur site preserves evidence of ...
... become mandatory for the doctors to recommend the mothers of ... the first six months, excluding any solid foods. But that ... saying that feeding the babies on cereals in the earlier ... ,Jill Poole, M.D., assistant professor in the pulmonary, critical ...
Cached Medicine News:Health News:Differently Wired and Gay – Are They Children of a Lesser God 2Health News:Earlier Introduction of Solid Foods in Infants Could Prevent Wheat Allergy 2
... TF is a minimally invasive tension-free ... urinary incontinence resulting from urethral hypermobility ... The Stratasis TF Kit is designed ... retrograde placement. Supplied sterile in ...
Stratasis Urethral Sling is intended for implantation to reinforce soft tissues where weakness exists. Supplied sterile in peel-open packages. Intended for one-time use....
... Roadrunner, Bentson, or other flexible tipped wire ... a redundant or tortuous ureteral segment. The ... and beyond a ureteral stone, or possibly ... from the mucosal wall. Supplied sterile in ...
Used for retrograde pyelogram. The tip configuration occludes the ureteral orifice and stabilizes the catheter by temporarily wedging in the orifice. Supplied sterile in peel-open packages. Intended ...
Medicine Products: